Johnson & Johnson $JNJ Shares Sold by HBK Sorce Advisory LLC

HBK Sorce Advisory LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 8.8% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 48,083 shares of the company’s stock after selling 4,661 shares during the period. HBK Sorce Advisory LLC’s holdings in Johnson & Johnson were worth $9,192,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. Avanza Fonder AB lifted its holdings in Johnson & Johnson by 6.6% in the third quarter. Avanza Fonder AB now owns 250,121 shares of the company’s stock valued at $46,377,000 after acquiring an additional 15,474 shares during the period. Horst & Graben Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 2.2% in the 3rd quarter. Horst & Graben Wealth Management LLC now owns 4,231 shares of the company’s stock valued at $785,000 after purchasing an additional 90 shares during the period. Uncommon Cents Investing LLC boosted its holdings in Johnson & Johnson by 0.4% during the third quarter. Uncommon Cents Investing LLC now owns 30,493 shares of the company’s stock worth $5,654,000 after buying an additional 124 shares in the last quarter. Capital Advisors Wealth Management LLC grew its position in Johnson & Johnson by 2.7% during the third quarter. Capital Advisors Wealth Management LLC now owns 3,033 shares of the company’s stock valued at $562,000 after buying an additional 81 shares during the period. Finally, Borer Denton & Associates Inc. increased its holdings in Johnson & Johnson by 0.9% in the third quarter. Borer Denton & Associates Inc. now owns 63,260 shares of the company’s stock valued at $11,730,000 after buying an additional 560 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on JNJ shares. HSBC reissued a “buy” rating and set a $240.00 target price on shares of Johnson & Johnson in a research note on Wednesday, December 10th. Stifel Nicolaus raised their price objective on Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a report on Wednesday, October 15th. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $212.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Citigroup increased their target price on Johnson & Johnson from $215.00 to $232.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Finally, Daiwa Capital Markets raised shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target for the company in a report on Monday, October 20th. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $210.25.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $207.54 on Monday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The stock’s 50 day simple moving average is $199.67 and its 200-day simple moving average is $181.22. The company has a market cap of $500.02 billion, a PE ratio of 20.03, a price-to-earnings-growth ratio of 2.25 and a beta of 0.36. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $215.18.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.